

# NOVACYT

**Avertissement aux actionnaires:**  
**Une version en français de ce document sera publiée dès que possible.**

**Novacyt S.A.**  
**(“Novacyt” or the “Company”)**

## **Director/PDMR Shareholding**

**Paris, France, and Manchester, UK – 30 March 2026** - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it has been notified that, on 26 and 27 March 2026, the following Directors purchased ordinary shares of €1/15 each in the Company (the “Ordinary Shares”):

<b>Director</b>	<b>Title</b>	<b>Number of Ordinary Shares purchased</b>	<b>Average price paid per Ordinary Share</b>	<b>Resultant beneficial holding</b>	<b>% of issued share capital</b>
<b>Lyn Rees</b>	CEO	73,379	€0.3899	73,379	0.00%
<b>John Brown</b>	Chairman	73,762	€0.3899	73,762	0.00%
<b>Ian Gilham</b>	NED	28,750	£0.34415	28,750	0.00%

## **Contacts**

### **Novacyt SA**

Lyn Rees, Chief Executive Officer  
Steve Gibson, Chief Financial Officer

<https://novacyt.com/investors>

**Via Walbrook PR**

### **SP Angel Corporate Finance LLP (Nominated Adviser and Broker)**

Matthew Johnson / Charlie Bouverat (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

### **Singer Capital Markets (Joint Broker)**

Phil Davies / James Fischer / Samed Ethem

+44 (0) 20 7496 3000

### **Allegra Finance (French Listing Sponsor)**

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10  
[r.durgetto@allegrafinance.com](mailto:r.durgetto@allegrafinance.com) / [y.petit@allegrafinance.com](mailto:y.petit@allegrafinance.com)

### **Walbrook PR (Financial PR & IR)**

Paul McManus / Lianne Applegarth  
Alice Woodings

+44 (0)20 7933 8780 or [novacyt@walbrookpr.com](mailto:novacyt@walbrookpr.com)  
+44 (0)7980 541 893 / +44 (0)7584 391 303  
+44 (0)7407 804 654

NOVACYT  
GROUP

An international molecular diagnostics company,  
providing a broad portfolio of clinical and research  
use only products, and instrumentation

PRIMER  
DESIGN

Yourgene  
Health

SCD  
SOUTHERN CROSS  
DIAGNOSTICS

**About Novacyt Group** ([www.novacyt.com](http://www.novacyt.com))

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

- |                          |   |
|--------------------------|---|
| <b>Clinical</b>          | Broad portfolio of human clinical <i>in vitro</i> diagnostic products, workflows and services focused on three therapeutic areas: <ul style="list-style-type: none"><li>• Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests</li><li>• Precision Medicine: DPYD genotyping assay</li><li>• Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel</li></ul>                           |
| <b>Instrumentation</b>   | Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: <ul style="list-style-type: none"><li>• Ranger® Technology: automated DNA sample preparation and target enrichment technology</li><li>• genesig q16 and q32 real-time quantitative PCR (qPCR) instruments</li></ul>   |
| <b>Research Use Only</b> | Range of services for the life sciences industry: <ul style="list-style-type: none"><li>• Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry</li><li>• Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)</li></ul> |

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them**

1.	Details of the person discharging managerial responsibilities / person closely associated																					
a)	Name 1) Lyn Rees 2) John Brown 3) Ian Gilham	1) CEO 2) Chairman 3) NED																				
2.	Reason for the Notification																					
a)	Position/status	See 1(a) - classified as a PDMR of the Company																				
b)	Initial notification/ Amendment	Initial Notification																				
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor																					
a)	Name	Novacyt S.A.																				
b)	LEI	213800BWAC2BF295EG28																				
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted																					
a)	Description of the Financial instrument, type of instrument	ordinary shares of €1/15 each																				
	Identification code	FR0010397232																				
b)	Nature of the transaction	Acquisition of Ordinary Shares																				
c)	Price(s) and volume(s) 1) Lyn Rees  2) John Brown  3) Ian Gilham	<table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>€0.3817</td> <td>15,149</td> </tr> <tr> <td>€0.3919</td> <td>56,438</td> </tr> <tr> <td>€0.3945</td> <td>1,792</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>€0.3817</td> <td>15,228</td> </tr> <tr> <td>€0.3919</td> <td>56,732</td> </tr> <tr> <td>€0.3950</td> <td>1,802</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>£0.34415</td> <td>28,750</td> </tr> </tbody> </table>	Price	Volume	€0.3817	15,149	€0.3919	56,438	€0.3945	1,792	Price	Volume	€0.3817	15,228	€0.3919	56,732	€0.3950	1,802	Price	Volume	£0.34415	28,750
Price	Volume																					
€0.3817	15,149																					
€0.3919	56,438																					
€0.3945	1,792																					
Price	Volume																					
€0.3817	15,228																					
€0.3919	56,732																					
€0.3950	1,802																					
Price	Volume																					
£0.34415	28,750																					
d)	Aggregated information: · Aggregated volume · Price  1) Lyn Rees  2) John Brown  3) Ian Gilham	<table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>€0.3899</td> <td>73,379</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>€0.3899</td> <td>73,762</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>£0.34415</td> <td>28,750</td> </tr> </tbody> </table>	Price	Volume	€0.3899	73,379	Price	Volume	€0.3899	73,762	Price	Volume	£0.34415	28,750								
Price	Volume																					
€0.3899	73,379																					
Price	Volume																					
€0.3899	73,762																					
Price	Volume																					
£0.34415	28,750																					
e)	Date of the transaction	1 & 2) 26 and 27 March 2026 3) 27 March 2026																				
f)	Place of the transaction	1 & 2) Euronext and 3) AIM																				